This content is not available in your region

Novartis boosts 2019 outlook on rising Cosentyx, Entresto sales

Access to the comments Comments
By Reuters
Novartis boosts 2019 outlook on rising Cosentyx, Entresto sales
FILE PHOTO: Switzerland's national flag flies in front of the logo of Swiss drugmaker Novartis in Basel, Switzerland, January 30, 2019. REUTERS/Arnd Wiegmann/File Photo   -   Copyright  Arnd Wiegmann(Reuters)

ZURICH (Reuters) – Swiss drugmaker Novartis on Wednesday raised its 2019 guidance after a first-quarter earnings and sales beat, as revenue from its heart failure drug Entresto and psoriasis medicine Cosentyx continued to grow.

First-quarter core net income rose 13 percent at constant exchange rates to $2.81 billion (£2.17 billion), compared to the $2.76 billion average estimate in a poll by Infront Data. Sales excluding Alcon, spun off to shareholders this month, rose 7 percent to $11.1 billion, compared to the $10.9 billion poll average.

Novartis now expects core operating income growth at a high-single-digit percentage rate, with sales growing in the mid-single-digit percentage range. It had seen net sales growing by a low- to mid-single-digit percentage, with core operating income up at a mid-single-digit rate.

(Reporting by John Miller; Editing by Michael Shields)